Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.
Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review. The companies had applied ...
A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...
Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...
Gallbladder problems are a common complication in individuals with sickle cell disease. These issues often arise due to the breakdown of red blood cells and the subsequent formation of gallstones ...
New York City Mayor Eric Adams is expected to meet with Director of Immigration and Customs Enforcement this week. As CBS ...
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...
2don MSN
UPMC said that it will soon require all patients, visitors, support persons and staff to wear masks in its patient care areas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback